Format

Send to

Choose Destination
Mol Cells. 2018 Jul 31;41(7):613-621. doi: 10.14348/molcells.2018.0143. Epub 2018 Jun 12.

Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells: Current Strategies and Limitations.

Author information

1
University of Toronto, Hospital of Sick Children, Toronto, Canada.
2
Emory University, Department of Biology, Atlanta, Georgia, USA.
3
Department of Physical Education, Dongguk University Seoul, Seoul 04620, Korea.
4
Department of Biomedical Sciences, City University of Hong Kong, Hong Kong.

Abstract

The capacity of differentiation of human pluripotent stem cells (hPSCs), which include both embryonic stem cells and induced pluripotent stem cells, into cardiomyocytes (CMs) in vitro provides an unlimited resource for human CMs for a wide range of applications such as cell based cardiac repair, cardiac drug toxicology screening, and human cardiac disease modeling. However, their applicability is significantly limited by immature phenotypes. It has been well known that currently available CMs derived from hPSCs (hPSC-CMs) represent immature embryonic or fetal stage CMs and are functionally and structurally different from mature human CMs. To overcome this critical issue, several new approaches aiming to generate more mature hPSC-CMs have been developed. This review describes recent approaches to generate more mature hPSC-CMs including their scientific principles, advantages, and limitations.

KEYWORDS:

cardiomyocytes; human pluripotent stem cells; immaturity; maturation

PMID:
29890820
PMCID:
PMC6078855
DOI:
10.14348/molcells.2018.0143
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Publishing M2Community Icon for PubMed Central
Loading ...
Support Center